Thienopyrimidine with phosphodiesterase V inhibiting effect

US6130223A · kind A · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Rochus Jonas · Darmstadt, DE
• Pierre Schelling · Mühltal, DE
• Maria Christadler · Darmstadt, DE
• Franz-Werner Kluxen · Darmstadt, DE

Key dates

• Filing date: Jun 11, 1999
• Grant date: Oct 10, 2000
• Expiry date: Jun 11, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to thienopyrimidine of the formula (I) as well as to their physiologically acceptable salts, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and n have the meaning cited in claim 1. Said compounds exhibit a phosphodiesterase V inhibition and can be used in the treatment of cardiovascular dieases and for the treatment and/or therapy potency disorder. ##STR1##